United States
R. A. Sperling, Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., Park, D. C., Reiman, E. M., Rowe, C. C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M. C., Thies, B., Morrison-Bogorad, M., Wagster, M. V., and Phelps, C. H.,
“Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.”,
Alzheimers Dement, vol. 7, no. 3, pp. 280-92, 2011.
Treatment Failure
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
tau Proteins
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
Severity of Illness Index
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
Practice Guidelines as Topic
R. A. Sperling, Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., Park, D. C., Reiman, E. M., Rowe, C. C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M. C., Thies, B., Morrison-Bogorad, M., Wagster, M. V., and Phelps, C. H.,
“Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.”,
Alzheimers Dement, vol. 7, no. 3, pp. 280-92, 2011.
Neuropsychological Tests
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
National Institute on Aging (U.S.)
R. A. Sperling, Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., Park, D. C., Reiman, E. M., Rowe, C. C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M. C., Thies, B., Morrison-Bogorad, M., Wagster, M. V., and Phelps, C. H.,
“Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.”,
Alzheimers Dement, vol. 7, no. 3, pp. 280-92, 2011.
Male
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
Intention to Treat Analysis
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
Humans
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
R. A. Sperling, Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., Park, D. C., Reiman, E. M., Rowe, C. C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M. C., Thies, B., Morrison-Bogorad, M., Wagster, M. V., and Phelps, C. H.,
“Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.”,
Alzheimers Dement, vol. 7, no. 3, pp. 280-92, 2011.
Female
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
Double-Blind Method
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
Cognition Disorders
R. A. Sperling, Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., Park, D. C., Reiman, E. M., Rowe, C. C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M. C., Thies, B., Morrison-Bogorad, M., Wagster, M. V., and Phelps, C. H.,
“Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.”,
Alzheimers Dement, vol. 7, no. 3, pp. 280-92, 2011.
Cognition
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
Biomarkers
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
R. A. Sperling, Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., Park, D. C., Reiman, E. M., Rowe, C. C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M. C., Thies, B., Morrison-Bogorad, M., Wagster, M. V., and Phelps, C. H.,
“Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.”,
Alzheimers Dement, vol. 7, no. 3, pp. 280-92, 2011.
Apolipoproteins E
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
Antibodies, Monoclonal, Humanized
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
Amyloid beta-Peptides
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
Alzheimer Disease
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
R. A. Sperling, Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., Park, D. C., Reiman, E. M., Rowe, C. C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M. C., Thies, B., Morrison-Bogorad, M., Wagster, M. V., and Phelps, C. H.,
“Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.”,
Alzheimers Dement, vol. 7, no. 3, pp. 280-92, 2011.
Aged, 80 and over
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
Aged
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
Activities of Daily Living
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.